Exclusive Online Content
GeoVax Announces Issuance of Cancer Vaccine Patent
GeoVax Labs, Inc. recently announced the U.S. Patent and Trademark Office has issued Patent No. 11278607 to GeoVax, pursuant to the company’s patent application No. 16/068,527 titled….
Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for Investigational Gene-Based Treatment to Address the Underlying Biology of Aging Skin
Jeune Aesthetics, Inc., a wholly owned subsidiary of Krystal Biotech, Inc., recently announced positive proof-of-concept efficacy data from Cohort 2 of the PEARL-1 study of KB301….
Lonza Partners With Oasmia Pharmaceuticals to Manufacture Ovarian Cancer Therapy
Oasmia Pharmaceutical AB and Lonza recently announced the companies have signed a large-scale manufacturing agreement for the main drug intermediate in the supply of….
Chiesi & Protalix Announce Phase 3 Data From BRIGHT Study in Fabry Disease
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., recently announced final results from the BRIGHT Phase 3 clinical trial evaluating pegunigalsidase alfa….
physIQ & CellCarta Collaborate to Accelerate a More Precise, Personalized Approach to Vaccine Development
physIQ and CellCarta recently announced a strategic collaboration to undertake a groundbreaking study with the potential to revolutionize vaccine development…..
PAVmed Announces Successful First-in-Human Implantations of its Intraosseous Infusion System
PAVmed Inc. recently announced physicians at the Clinica Porto Azul in Barranquilla, Colombia, successfully implanted the company’s PortIO Intraosseous Infusion System in three….
PathAI Partners With Datavant to Enable Biopharma Companies to Connect Digital Pathology Data for Research
PathAI and Datavant recently announced a collaboration to enable compliant connectivity of PathAI’s pathology platform to life sciences trial data and other real-world data…..
Innoforce & Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies
Innoforce and Hibiscus BioVentures recently announced they have formed a strategic partnership to leverage the combined resources of both organizations to advance new Advanced Therapy Medicinal Products (ATMPs) and biologic medicines in order to….
Biogen & Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
Biogen Inc. and Eisai Co., Ltd. recently announced the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the US as ADUHELM (aducanumab-avwa)…..
Eyenovia Announces Positive Study Results Demonstrating its Optejet Delivery Technology Reduces Conjunctival Cell Toxicity From Preserved Ophthalmic Solutions to a Level Comparable With Non-Preserved Solutions
Eyenovia, Inc. recently announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface….
NeuBase Therapeutics Presents New Preclinical Data for its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution & Myotonia Reversal
NeuBase Therapeutics, Inc. recently announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1 (DM1). ….
Synthetic Biologics Completes Acquisition of VCN Biosciences
Synthetic Biologics, Inc. recently announced it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions…..
Vetter’s Extraordinary Performance Sweeps the Board at the 2022 CMO Leadership Awards
Vetter recently announced it has won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service…..
Evonik Launches New Technology to Improve Solubility of Oral Small Molecules
Evonik recently announced it now offers EUDRATEC SoluFlow, a new microparticle technology to enhance solubility of active pharmaceutical ingredients in oral drug products…..
Novartis, Voyager Therapeutics Reach License Option Agreement
Novartis recently announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three….
Adaptive Research & UBERDOC Announce Collaboration
Adaptive Research and UBERDOC recently announced a collaboration to expand clinical trial access to the physicians and clinical trial sites….
BioNTech & Regeneron Expand Strategic Collaboration
BioNTech SE recently announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor….
Targovax ASA & Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON
Agenus and Targovax ASA recently announced they have entered into a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccines with Agenus´s clinically validated….
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial
Evaxion Biotech A/S has recently now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patients…..
Cambrex Expands Biopharmaceutical Services Business
Cambrex recently announced it is significantly expanding its existing biopharmaceutical testing services business. The expansion includes 11 additional cGMP….
